Embera NeuroTherapeutics, Inc. Closes Series A Funding, Starting FDA Trial Process

More info…

Embera NeuroTherapeutics, Inc., a start-up company developing novel treatments for a broad range of addictions, as well as other neuropsychiatric disorders, has secured over $800,000 of Series A financing that will help the company move its novel combinational drug into Phase 1b FDA trials.

(PRWeb February 08, 2007)

Read the full story at

meth rehab center

Leave a Comment

Previous post:

Next post: